Maze Therapeutics, Inc. Common Stock vs. Moderna, Inc. Common Stock
MAZE
Maze Therapeutics, Inc. Common Stock
$28.38 +26.75%
VS MRNAModerna, Inc. Common Stock
$172.94 +12.27%
Moderna, Inc. Common Stock (MRNA) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| MAZE | MRNA | |
|---|---|---|
| Market Cap | $1.24 billion | $61.50 billion |
| Revenue (TTM) | $20.00 million | $2.23 billion |
| Net Income (TTM) | $-133,590,000 | $-3,151,000,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| MAZE | MRNA | |
|---|---|---|
| Price / Book | 2.74 | 9.10 |
| Price / Sales | 62.19 | 27.60 |
MAZE and MRNA split the valuation factors evenly.
Profitability
| MAZE | MRNA | |
|---|---|---|
| Net Margin | -667.95% | -141.43% |
| Return on Equity | -29.48% | -46.61% |
MAZE and MRNA split the profitability factors evenly.
Risk & Sentiment
| MAZE | MRNA | |
|---|---|---|
| Short Interest | 2.15% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: MAZE overview, MAZE financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.